Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimaporfin-induced PCI of Antigen/Adjuvant in Healthy Subjects
NCT02947854Phase 1Completed
- Sponsor
- PCI Biotech
- Start
- Sep 2016
- Primary completion
- Mar 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of fimaporfin in HPV-related cancer (3 arms), sponsored by PCI Biotech. Primary endpoints: Incidence of Treatment Emergent Adverse Events up to 1 year, Incidence of abnormal and clinical significant measures up to 1 year and 2 more. Started Sep 2016; status: completed.
02
Drugs
fimaporfin
03
Conditions
HPV-related cancer
Beyond the preview
Go deeper on NCT02947854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947854.